Sinus Tarsi Implant as an Adjuvant Procedure to Medial Displacement Calcaneal Osteotomy in the Treatment of Mobile Adult Acquired Flatfoot Deformity

MDCO is a commonly used procedure with few complications. However, the medial displacement of the calcaneus only aims to correct the deformity in one plane despite AAFD being a deformity of three planes with hypereversion of the calcaneus, anterior translation of the talus over the calcaneus and tilting/drop of the calcaneal head. Because of these multiple forces, the healing of MDCO in the intended position can sometimes be difficult to achieve and medial soft tissue is still stressed leading to recurring deformity. The sinus tarsi implant (STI) has been described to function as an internal splint, protecting soft tissue procedures on the medial side, reversing anterior translation of the talus, opposing calcaneal eversion, and lifting talar head. This is suggested to create a better correction of the deformity with enhanced appearance of the foot and potentially better long-term functional results.

Methods

Trial design and setting The study is a prospective multicenter randomized controlled trial conducted at nine orthopedic centers in Sweden. The participating centers are Hässleholm hospital, Skåne University Hospital in Malmö, Capio Ortho Center in Malmö and Göteborg, Sahlgrenska University hospital in Mölndal, Uppsala University Hospital, Falun Hospital, Östersund Hospital, Eksjö Hospital and Växsjö Hospital.

Screening

Patients referred to the orthopedic department at the participating centers will be evaluated by an orthopedic specialist with history and clinical examination. There will usually be radiographic imaging done before the visit. With clinical and radiographic examination, the surgeon can usually establish a diagnosis of AAFD and decide whether surgical treatment is indicated. Patients judged to fulfil the eligibility criteria are then given, by the surgeon, full verbal and written information about the aims and conduct of the trial as well as potential advantages and disadvantages of participation. Patients who accept participation will provide written informed consent.

Patients who consent to participate will undergo baseline assessment at another appointment scheduled between the screening and the date of surgery.

Randomization

Patients are centrally randomized according to a computer-generated randomization list (ratio 1:1). The randomization is stratified according to patient sex and is done in random blocks of various sizes.

Follow-up procedures

Patients will complete a questionnaire consisting of two PROMs, the generic EuroQol 5 Dimensions (EQ-5D) and the Self-reported Foot and Ankle Score (SEFAS) as well as 5 additional questions regarding how pleased (satisfied) the patients are with the appearance of the foot, the shoes they are able to wear, foot strength, stability, and their overall satisfaction with the results of the surgery (this question will be included in the postoperative questionnaire). The questionnaires will be completed at baseline, 4-5, 12, and 24 months postoperatively. At these follow-up visits, the patients will also be clinically examined by a physiotherapist or nurse, and radiographic examination will be done. The trial coordinator will monitor completeness of questionnaires and use telephone contact when necessary. Participants are informed, in writing and during examination/follow-up, about the importance of completing the follow-up questionnaires and examinations. Patients can choose to discontinue study participation at any given time point without being obliged to an explanation.

Outcome measures

Changes in the alignment of the foot will be assessed with weight-bearing radiographs measuring specific angles and positions described below.

The EQ-5D is a validated generic PROM that assess health status and health-related quality of life from 5 different dimensions. The 5 dimensions are summarized in an index where 1 represents best health status and 0 the lowest health status. In the EQ-5D, the patient can also estimate their general health on a scale from 0 to 100 on a visual analog scale (VAS). EQ-5D sex-specific, country-specific, and age-specific normative values are available, which makes comparison between a healthy population and the study participants possible.

Self-reported Foot and Ankle Score (SEFAS) is a foot- and ankle-specific PROM based on the New Zealand total ankle questionnaire (NZAQ) and the Swedish version has been created according to a standardized cross-cultural adaption procedure. The PROM contains different dimensions including pain, function, and activity limitations. The different dimensions are summarized into a total score where 0 represents most severe disability and 48 represents normal function. A system has been created for handling of incorrect completion or missing answers in the SEFAS. The SEFAS has been validated for foot and ankle disorders. Gender- and age-specific normative values have also been collected for the Swedish population and the minimal important change (MIC) value have been calculated for SEFAS. A change in SEFAS score of 5 units is considered clinically relevant.

Pain will be measured with a visual analog scale (VAS) asking the patients to rate (on 0 to 100 scale) their pain severity.

Satisfaction will be assessed with five additional questions on a five item Likert scale:

1. How satisfied is the participant with the appearance of his/her foot? 2. How satisfied is the participant with the shoes he/she is able to wear? 3. How satisfied is the participant with the strength of the foot? 4. How satisfied is the participant with the stability of the foot? 5. How satisfied is the participant with the results of the surgery (not applicable at baseline assessment)? The participants will also answer a question about the duration of postoperative sick leave in the postoperative questionnaires.

Physical examination

The physical examinations will be performed by a physiotherapist or a nurse and will include evaluation of single heel-rise height (cm from the lowest part of the heel to the floor) and endurance (number of performed heel-rises). The examiner will be blinded to group allocation and steristrips will be placed in front of the lateral malleolus in order to cover surgical scars that may be located there.

Radiographic examination Meary's angle is the angle between the midline of talus and the midline of the first metatarsal bone on a lateral view radiograph. In a normally configurated foot this angle is approximately 0 degrees. In the flatfoot, talus frontal portion collapses towards the floor which increases Meary's angle that becomes greater the more talus collapses downward. Radiographic examination will include foot and ankle (frontal projection and from the side) at weight-bearing.

Presence of malalignment of the ankle fork will be noted from the frontal projection of the ankle and the Salzman view. CT or MRI will not be performed pre- or postoperatively if there is no specific reason, in that case, reported by the treating surgeon.

Adherence

In written information, before randomization, and during all contacts with the research team the trial participants will be informed about the importance of remaining in the trial, completing the questionnaires, and participating in the follow-up examinations.

Postoperative regimes Patients will receive external fixation in the form of a cast postoperatively. Patients who have undergone Cotton osteotomy will wear the cast for 8 weeks postoperatively and will not be allowed to bear weight on the operated foot for three weeks postoperatively. Patients who have not undergone a Cotton osteotomy will wear the cast for 6 weeks postoperatively and will bear weight on the operated side immediately postoperatively. When the patients start bearing weight postoperatively, they will use crutches for support.

Surgery

Surgery will be done by experienced foot and ankle surgeons, defined as orthopedic specialists (senior consultants) with at least 15 forefoot and/or 5 hindfoot procedures yearly, at the participating centers.

Assessment of safety

During the conduct of the trial, the investigator will report all adverse events. All adverse events will be followed up until resolved or as clinically required. Adverse events may be reported spontaneously by the patient or elicited through open questioning during and at the end of the trial. Participants are informed to contact the trial therapists or coordinator at the participating centers whenever they wish to discuss or report any events during the trial period. All reported or observed adverse events including type, intensity and duration will be recorded in a standard protocol. Any serious adverse events will be promptly reported to the steering and data monitoring committees and the trial sponsor. Extraction of the STI due to pain/discomfort or other reason will be monitored and reported but not considered an adverse event or a reason for termination of the trial.

Assessment of costs

The investigators will assess the cost-effectiveness of the respective procedures by comparing duration of surgery, material costs, complication rate and potential need of additional health-care visits or procedures.

Withdrawals Patients can withdraw from the trial at any time without need to give reasons. Patients who do not wish to attend physical examination will be asked to complete the questionnaire.

Sample size

The primary outcome is change in Meary's angle from baseline to 1 year postoperatively. In previous studies investigating the degree of correction in Meary's angle from baseline to 1 year after MDCO in patients with AAFD stage IIa, a mean correction of 10 degrees has been reported.

Assuming a mean correction of Meary's angle of 10 degrees (SD 10) after MDCO and 15 degrees (SD 10) after MDCO with an adjuvant STI, 80% power and p\<0.05, a sample size of 63 patients in each trial arm will be required. The investigators aim to recruit 130 patients (65 in each treatment group) because of potential dropouts.

Statistical analysis

For continuous endpoints (radiographic measurements, SEFAS score, EQ-5D index, heel-rise height and endurance, duration of sick-leave) mean values and standard deviations will be calculated. For categorical variables, such as adverse events, and satisfaction assessment, proportions will be calculated. Statistical tests will be performed according to the intention-to-treat principle. An exploratory as-treated analysis will also be performed.

Both hypothesis-generating and confirmatory testing will be performed, the latter for the primary endpoints.

Primary analysis: The mean degree change in Meary's angle from baseline to 12 months postoperative (primary outcome) will be compared using paired samples t-test.

Secondary analyses:

Mean change in residual radiographic measurements, SEFAS score and EQ5D index, clinical tests, duration of sick-leave will be investigated using paired samples t-test. Adverse events and satisfaction assessment will be presented in tables.

• Meary's angle [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5 and 24 months postoperatively]
• Calcaneal inclination angle [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• Talar declination angle [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• Talar-2nd metatarsal angle [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• Talar coverage angle [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• Talar uncoverage [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• Medial cuneiform height [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• Angle between tibial and calcaneal midline [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• SEFAS change [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• EQ5D-3L change [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• VAS change [Time frame: From baseline/preoperatively (max 6 months preoperatively) to 4-5, 12, and 24 months postoperatively]
• Degree of satisfaction regarding the results of the surgery [Time frame: Measured at 4-5, 12, and 24 months postoperatively]